Novo Nordis Short

2024年9月19日

Shorting Novo Nordisk may be considered due to potential overvaluation, rising competition in diabetes and obesity markets, supply chain challenges, and risks from patent expirations. Regulatory hurdles, slower demand in key regions, and macroeconomic factors like healthcare budgets and inflation could further impact growth. However, thorough analysis is essential, as shorting carries high risk.

2024年9月26日

註釋

at the neckline, could have a bit of oscillation, but once break down $120, heading to the target $100.

2024年9月29日

註釋

Neckline broke, any small fundamental issue would incur the acceleration to the target

2024年10月25日

註釋

will close half of my put position when it hits below $110 prior to the earning, that would give the trade a 75% profit

2024年11月12日

交易結束：目標達成

Closed my position.